The Pharmacy Times® Cardiovascular Health Resource Center is a comprehensive resource for clinical news and expert insights on the health of the heart and blood vessels, including coronary heart disease, stroke, heart failure, heart arrhythmias, and heart valve issues.
July 26th 2024
Pharmacologic approaches can increase the use of injectables.
Maximizing Patient Outcomes Through Pharmacist-Led Homozygous Familial Hypercholesterolemia Management
1.0 Credit / Cardiology
View More
Setting the Stage: An Introduction to Worsening Heart Failure Events in Patients With Heart Failure With Reduc...
1.0 Credit / Cardiology
View More
Navigating the Therapeutic Landscape of Homozygous Familial Hypercholesterolemia
1.0 Credit / Cardiology
View More
Understanding the Challenges of Homozygous Familial Hypercholesterolemia
1.0 Credit / Cardiology
View More
The Role of the Pharmacist in Optimizing DOAC Utilization Across Practice Settings
1.0 Credit / Cardiology
View More
Soluble Guanylate Cyclase Stimulators in the Management of Worsening Heart Failure With Reduced Ejection Fract...
1.0 Credit / Cardiology
View More
Individualizing Care for Patients With Heart Failure: The Role of the Pharmacist in Optimizing Education and I...
1.0 Credit / Cardiology
View More
Advancing Chronic Worsening Heart Failure Treatment: The Critical Role of Pharmacists in Therapy Integration
1.0 Credit / Cardiology
View More
Iron Deficiency and Anemia in Heart Failure: Clinical Applications for the Use of Intravenous Iron
1.5 Credits / Cardiology
View More
Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejec...
1.0 Credits / Cardiology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Optimizing Care for Chronic Worsening Heart Failure: The Key Role of Pharmacists in Integrating Therapies
1.5 Credits / Cardiology
View More
Lipoprotein(a) and Beyond: Emerging Paradigms in Atherosclerotic Cardiovascular Disease Prevention
1.5 Credits / Cardiology
View More
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney D...
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
1.5 Credits / Cardiology, Neurology, Rare Diseases
View More
The Evolving Treatment Paradigm for the Management of Pulmonary Arterial Hypertension: Strategies to Optimize ...
1.5 Credits / Cardiology
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Expanding Role of Nonstatin Therapies in Reducing LDL-Cholesterol Levels to Prevent and Manage ASCVD: A Re...
1.5 Credits / Cardiology
View More
Updated Guidelines in the Management of Atrial Fibrillation and Application for Pharmacists
1.5 Credits / Cardiology
View More
Elevating Cardiac Care: Insights From Pharmacists Across Practice Settings
1.0 Credit / Cardiology
View More
Recent Developments in the Management of Heart Failure With Preserved Ejection Fraction
1.0 Credit / Cardiology
View More
Therapies in Lowering LDL-Cholesterol Levels for the Primary and Secondary Prevention of Atherosclerotic Cardi...
0.75 Credit / Cardiology
View More
FDA Grants Fast Track Designation to Milvexian for Multiple Prospective Cardiovascular Indications
June 6th 2023The proposed indications for milvexian include stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.
Read More
Sotatercept Improves Exercise Capacity in Individuals With Pulmonary Arterial Hypertension
April 27th 2023The median change from baseline at week 24 in the 6-minute walk distance was 34.4 m in the sotatercept group and 1 m in the placebo group among patients with pulmonary arterial hypertension.
Read More
FDA Approves Evinacumab-dgnb for Young Children With Homozygous Familial Hypercholesterolemia
March 22nd 2023Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.
Read More